GLP-1 receptor agonists have proven to be a major therapeutic class in the treatment of obesity and T2DM due to their multi-metabolic mechanism of action. The pharmacological agents function in the same way as the endogenously produced GLP-1 by improving glucose-dependent insulin secretion, inhibition of glucagon secretion, slowing down of gastric emptying, and increasing satiety. As such, the agents result in better glycemic regulation as well as sustained weight loss. In addition to the multi-metabolic effects, GLP-1 receptor agonists have also been found to offer cardiovascular and kidney protection, and hence, are useful in individuals with multiple cardiometabolic risks. The agents have found application in areas other than the treatment of diabetes as well. In addition to being used in diabetes, the drugs are also used in chronic weight management and other obesity-related diseases. Current research is trying to investigate the utility of the drugs in metabolic dysfunction-associated steatotic liver disease, neurodegeneration, and precision medicine among other areas.
Gokulakrishnan D.1, Mirudula S.2, Kavya M.3, Saron Micahvel S.4, Dr. K. Bharathi Priya*5 (Thu,) studied this question.